Clinical Trial Update: Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating paclitaxel liposome plus cisplatin as first-line therapy for metastatic esophageal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Paclitaxel liposome (liposomal paclitaxel)

Snippet

Sponsor: Shantou University Medical College | Conditions: Esophageal Cancer | Phase 3 | Status: WITHDRAWN